Literature DB >> 25715450

[DNA repair XRCC1, XPD genes polymorphism as associated with the development of bladder cancer and renal cell carcinoma].

L Z Akhmadishina, I R Giliazova, L R Kutlyeva, G F Korytina, O V Kochetova, M F Urmantsev, S M Izmaĭlova, A A Izmaĭlov, G B Kunsbaeva, A A Zagidullin, A A Haliullin, V N Pavlov, T V Viktorova, E K Husnutdinova.   

Abstract

We examined the correlations between the polymorphic alleles of the DNA repair genes XRCC1 (c.839G> A, rs25489; and c.1196A> G, rs25487), XPA (c.-4A> G, rs1800975), and XPD (c.2251A> C, rs13181) and the progression and severity of neoplasias in the bladder and kidney in patients of three distinct ethnic groups, Bashkir, Russians, and Tatar, residing in the Republic of Bashkorostan. The study enrolled 468 cancer patients and 351 healthy individuals. Genotyping for polymorphic alleles was carried out using the PCR-RFLP method. We identified a correlation between allele A of the c.839 G>A locus of the XRCC1 gene and the incidence of the bladder cancer (BC) and kidney cancer (KC) in the Tatar study group, using the additive genetic effects model (Odds Ratio (OR) = 5.23 and OR = 3.90). In turn, the heterozygous G/A genotype was present at a significantly higher frequency in the KC patients of Bashkir ethnic origin, compared with the control group (p = 0.0061, OR= 4.72). Additional analysis with consideration of participants' smoking status showed that the G/A genotype is significantly more frequent in smokers with BC (OR = 1.96, p = 0.05) then in healthy smokers. We also determined, using the recessive genetic model, that the genotype A/A of the c. 1196A>G locus of the XRCC1 gene was correlated with a higher risk of BC in the Russian cohort (OR = 2.29, p = 0.0082) and an increased incidence of KC in the Bashkir group (OR = 4.06, p = 0.05). A similar correlation was obtained for smokers. In contrast, the allele c.2251 A>C in the XPD gene correlated with a lower risk for BC and KC in the Tatars (p = 0.0003, OR = 0.48 and p < 0.0001, OR = 0.37) in the additive model and in the Bashkirs (p = 0.0083, OR = 0.12) and Russians (p = 0.0001, OR = 0.14) in the recessive model. Further, we uncovered that polymorphism c.839 G>A in the XRCC1 gene contributes to the progression of noninvasive and invasive BC and promotes KC at early and advanced stages of the disease. Thus, we identified similar correlations between DNA repair gene polymorphism and the incidence and progression of BC and KC. We propose that this result points to the involvement of common pathogenetic mechanisms in the initiation and progression of the urinary neoplasias.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25715450

Source DB:  PubMed          Journal:  Genetika        ISSN: 0016-6758


  5 in total

1.  Permutation-based identification of important biomarkers for complex diseases via machine learning models.

Authors:  Xinlei Mi; Baiming Zou; Fei Zou; Jianhua Hu
Journal:  Nat Commun       Date:  2021-05-21       Impact factor: 14.919

2.  Correlation between XRCC1 Arg399Gln genetic polymorphisms and susceptibility to bladder cancer: a meta-analysis.

Authors:  Nannan Liu; Xiawei Fei; Yi Shen; Weifeng Shi; Jinhong Ma
Journal:  Onco Targets Ther       Date:  2016-01-28       Impact factor: 4.147

3.  Association of human XPA rs1800975 polymorphism and cancer susceptibility: an integrative analysis of 71 case-control studies.

Authors:  Maoxi Yuan; Chunmei Yu; Kuiying Yu
Journal:  Cancer Cell Int       Date:  2020-05-13       Impact factor: 5.722

4.  DNA Repair Gene Polymorphisms and Susceptibility to Urothelial Carcinoma in a Southeastern European Population.

Authors:  Maria Samara; Maria Papathanassiou; Lampros Mitrakas; George Koukoulis; Panagiotis J Vlachostergios; Vassilios Tzortzis
Journal:  Curr Oncol       Date:  2021-05-14       Impact factor: 3.677

5.  The study on copy number alteration of clear cell renal cancer in Chinese population.

Authors:  Ning Zhang; Siteng Chen; Guangliang Jiang; Yishuo Wu; Jialiang Shao; Wennuan Liu; Xiang Wang; Rong Na; Jianfeng Xu
Journal:  J Cancer       Date:  2020-01-01       Impact factor: 4.207

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.